Search Results - gp120

6 Results

Sort By:

High Efficacy Vaccine and Microbicide Combination For Use Against HIV

Abstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Marjorie Robert-Guroff, Daniel Appella, Sabrina Helmold Hait, Mohammed Rahman, Massimiliano Bissa, Ettore Appella, Lisa Marie Jenkins, Isabela Silva De Castro

Keywords(s): Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Vaccines

Novel Fusion Proteins for HIV Vaccine

Abstract: Development of successful HIV vaccine immunogens continues to be a major challenge. Although gp120 was identified as having significant potential as a vaccine immunogen, attempts to elicit broadly neutralizing antibodies using recombinant gp120 failed. The highly flexible gp120 may present numerous conformations to the humoral immune system...

Published: 7/25/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen

Keywords(s): ANTIBODY, CD4, Dimitrov, fusion protein, gp120, HIV Vaccine

Category(s): TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Immunogens for Use in a High Efficacy HIV Vaccine

Abstract: Human immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral treatments have been effective in preventing spread of the virus and active outbreaks of acquired immune deficiency syndrome (AIDS). However, the development and deployment of an effective vaccine would provide long-lasting...

Published: 8/14/2024 | Inventor(s): Genoveffa Franchini, Timothy Cardozo, Isabela Silva De Castro, Giacomo Gorini, Massimiliano Bissa, Manuel Becerra-Flores

Keywords(s): AIDS, Franchini, GLYCOPROTEIN, gp120, HIV, Human Immunodeficiency Virus, V1, V2, Vaccine, Variable Envelope Region

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...

Published: 7/25/2024 | Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola

Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein

This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein...

Published: 7/25/2024 | Inventor(s): Raffaello Cimbro, Paolo Lusso

Keywords(s): BETWEEN, CD4, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, Envelope, gp120, HIV, INHIBIT, INTERACTION, Mimics, Peptide, Protein, RECEPTOR, That, V2-loop, VLXXXX, WIXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX, YFXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Therapeutics, Application > Vaccines

The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection

This invention involves the use of inhibitors of alpha-4 beta-7 (a4b7) integrin to inhibit HIV transmission/infection, as a prophylactic to inhibit onset of the acute stage of HIV infection or to treat HIV infection. The a4b7 integrin inhibitors were previously developed for use in other diseases, such as multiple sclerosis or inflammatory bowel disease. a4b7...

Published: 7/25/2024 | Inventor(s): Anthony Fauci, Claudia Cicala, Diana Goode, James Arthos

Keywords(s): ANTAGONISTS, BBXXXX, BETWEEN, DB4AXX, DB4XXX, DBXXXX, Direct, DXXXXX, gp120, HIV, INTERACTION, Intregrin, VLXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease